These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

256 related items for PubMed ID: 32250714

  • 1. Efficacy of brodalumab in the treatment of scalp and nail psoriasis: results from three phase 3 trials.
    Elewski B, Rich P, Lain E, Soung J, Lewitt GM, Jacobson A.
    J Dermatolog Treat; 2022 Feb; 33(1):261-265. PubMed ID: 32250714
    [Abstract] [Full Text] [Related]

  • 2. Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis.
    Lebwohl M, Strober B, Menter A, Gordon K, Weglowska J, Puig L, Papp K, Spelman L, Toth D, Kerdel F, Armstrong AW, Stingl G, Kimball AB, Bachelez H, Wu JJ, Crowley J, Langley RG, Blicharski T, Paul C, Lacour JP, Tyring S, Kircik L, Chimenti S, Callis Duffin K, Bagel J, Koo J, Aras G, Li J, Song W, Milmont CE, Shi Y, Erondu N, Klekotka P, Kotzin B, Nirula A.
    N Engl J Med; 2015 Oct; 373(14):1318-28. PubMed ID: 26422722
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and Safety of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis and Skin of Color: Results from the Pooled AMAGINE-2/-3 Randomized Trials.
    McMichael A, Desai SR, Qureshi A, Rastogi S, Alexis AF.
    Am J Clin Dermatol; 2019 Apr; 20(2):267-276. PubMed ID: 30471012
    [Abstract] [Full Text] [Related]

  • 4. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
    Spuls PI, Hooft L.
    Br J Dermatol; 2012 Oct; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
    [Abstract] [Full Text] [Related]

  • 5. Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasis.
    Langley RG, Rich P, Menter A, Krueger G, Goldblum O, Dutronc Y, Zhu B, Wei H, Cameron GS, Heffernan MP.
    J Eur Acad Dermatol Venereol; 2015 Sep; 29(9):1763-70. PubMed ID: 25693783
    [Abstract] [Full Text] [Related]

  • 6. Improvement in itch and other psoriasis symptoms with brodalumab in phase 3 randomized controlled trials.
    Gottlieb AB, Gordon K, Hsu S, Elewski B, Eichenfield LF, Kircik L, Rastogi S, Pillai R, Israel R.
    J Eur Acad Dermatol Venereol; 2018 Aug; 32(8):1305-1313. PubMed ID: 29512200
    [Abstract] [Full Text] [Related]

  • 7. Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator-controlled phase 3 AMAGINE-2 trial.
    Puig L, Lebwohl M, Bachelez H, Sobell J, Jacobson AA.
    J Am Acad Dermatol; 2020 Feb; 82(2):352-359. PubMed ID: 31175909
    [Abstract] [Full Text] [Related]

  • 8. Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3.
    Papp KA, Gordon KB, Langley RG, Lebwohl MG, Gottlieb AB, Rastogi S, Pillai R, Israel RJ.
    Br J Dermatol; 2018 Aug; 179(2):320-328. PubMed ID: 29488226
    [Abstract] [Full Text] [Related]

  • 9. Comparable efficacy and safety of brodalumab in obese and nonobese patients with psoriasis: analysis of two randomized controlled trials.
    Hsu S, Green LJ, Lebwohl MG, Wu JJ, Blauvelt A, Jacobson AA.
    Br J Dermatol; 2020 Apr; 182(4):880-888. PubMed ID: 31276189
    [Abstract] [Full Text] [Related]

  • 10. Brodalumab: A Review in Moderate to Severe Plaque Psoriasis.
    Blair HA.
    Drugs; 2018 Mar; 78(4):495-504. PubMed ID: 29516365
    [Abstract] [Full Text] [Related]

  • 11. Complete clearance and Psoriasis Area and Severity Index response for brodalumab and ustekinumab by previous treatment history in AMAGINE-2 and AMAGINE-3.
    Reich K, Hansen JB, Puig L, Konstantinou MP, Warren RB.
    J Eur Acad Dermatol Venereol; 2021 Oct; 35(10):2034-2044. PubMed ID: 34076919
    [Abstract] [Full Text] [Related]

  • 12. Brodalumab Is Associated with High Rates of Complete Clearance and Quality of Life Improvement: A Subgroup Analysis of Patients with Psoriasis and Concomitant Psoriatic Arthritis.
    Kokolakis G, Vadstrup K, Hansen JB, Carrascosa JM.
    Dermatology; 2022 Oct; 238(4):620-629. PubMed ID: 34823247
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of brodalumab in the Korean population for the treatment of moderate to severe plaque psoriasis: A randomized, phase III, double-blind, placebo-controlled study.
    Seo SJ, Shin BS, Lee JH, Jeong H.
    J Dermatol; 2021 Jun; 48(6):807-817. PubMed ID: 33373480
    [Abstract] [Full Text] [Related]

  • 14. Complete clearance and psoriasis area and severity index response for brodalumab and ustekinumab in AMAGINE-2 and -3.
    Warren RB, Hansen JB, Reich K, Paul C, Puig L.
    J Eur Acad Dermatol Venereol; 2021 Feb; 35(2):450-457. PubMed ID: 32662540
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of brodalumab in patients with psoriasis who had inadequate responses to ustekinumab: subgroup analysis of two randomized phase III trials.
    Langley RG, Armstrong AW, Lebwohl MG, Blauvelt A, Hsu S, Tyring S, Rastogi S, Pillai R, Israel R.
    Br J Dermatol; 2019 Feb; 180(2):306-314. PubMed ID: 30328108
    [Abstract] [Full Text] [Related]

  • 16. Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis: results from PHOENIX 1.
    Rich P, Bourcier M, Sofen H, Fakharzadeh S, Wasfi Y, Wang Y, Kerkmann U, Ghislain PD, Poulin Y, PHOENIX 1 investigators.
    Br J Dermatol; 2014 Feb; 170(2):398-407. PubMed ID: 24117389
    [Abstract] [Full Text] [Related]

  • 17. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis.
    Papp KA, Reich K, Paul C, Blauvelt A, Baran W, Bolduc C, Toth D, Langley RG, Cather J, Gottlieb AB, Thaçi D, Krueger JG, Russell CB, Milmont CE, Li J, Klekotka PA, Kricorian G, Nirula A.
    Br J Dermatol; 2016 Aug; 175(2):273-86. PubMed ID: 26914406
    [Abstract] [Full Text] [Related]

  • 18. Improvement of Nail and Scalp Psoriasis Using Apremilast in Patients With Chronic Psoriasis: Phase 2b and 3, 52-Week Randomized, Placebo-Controlled Trial Results.
    Nguyen CM, Leon A, Danesh M, Beroukhim K, Wu JJ, Koo J.
    J Drugs Dermatol; 2016 Mar; 15(3):272-6. PubMed ID: 26954311
    [Abstract] [Full Text] [Related]

  • 19. Long-term efficacy and safety of brodalumab in moderate-to-severe plaque psoriasis: a post hoc pooled analysis of AMAGINE-2 and -3.
    Reich K, Iversen L, Puig L, Lambert J, Mrowietz U, Kaplan Saday K, Warren RB.
    J Eur Acad Dermatol Venereol; 2022 Aug; 36(8):1275-1283. PubMed ID: 35279890
    [Abstract] [Full Text] [Related]

  • 20. Adalimumab for the treatment of moderate to severe psoriasis: subanalysis of effects on scalp and nails in the BELIEVE study.
    Thaçi D, Unnebrink K, Sundaram M, Sood S, Yamaguchi Y.
    J Eur Acad Dermatol Venereol; 2015 Feb; 29(2):353-360. PubMed ID: 24846518
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.